This study aimed to assess effectiveness of a taurolidine based lock solution in preventing the infections of central venous catheter (CVC) in intensive care unit (ICU) cases.

The central venous catheter (CVC) is highly frequent in the intensive care unit (ICU), with an average use rate between 32% and 80% among adult ICU patients. The utilization of CVC in ICUs has escalated over the past decade, accompanied by a corresponding increase in problems related to their usage.

Taurolidine is a nontoxic substance having antibacterial impacts counter to mutually gram-positive and -negative bacteria, additionally to fungus. It decreases biofilm development and doesn't develop resistance to antibiotics, since it serves as an antiseptic rather than an antibiotic Consequently, it may function as a locking mechanism.

Inclusion Criteria:

• Age > 21 years.
• Both genders.
• Patients admitted to the intensive care unit (ICU) requiring central venous catheter insertion.

Exclusion Criteria:

• Cases with active infections, hemorrhage or bleeding disorders, infections within insertion place.
• History of allergy to taurolidine, tigecycline, heparin, and citrate.

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

After the end of study for one year.

The data will be available upon a reasonable request from the corresponding author.